Special Issue

Radiation-Induced (Osteo-)Immunological Alterations— Impact on Tumors, Inflammation and Radiation Protection

Message from the Guest Editors

Radiation exposure has long been thought to only affect the hereditary substance, namely the DNA, of cells. However, it has become more and more clearer that besides these so-called "targeted effects" of radiation exposure, a manifold of bystander, abscopal and generally systemic effects affecting the whole organism occur. Here, the immune system and its interaction with the skeletal system are major players. The close relationship between the immune system and the bone comes more and more in the focus of radiation research. Co-funding factors such as gender, age, and inflammatory basal status have additionally to be considered in analyses of individual responses to low, medium and high dose radiation exposure. In this Special Issue, we invite primary and review work to be submitted dealing with radiation effects on the immune system and/or the bone in connection to radiotherapy of tumor diseases, modulation of inflammation and radiation protection issues. We are looking forward to radiobiological approaches as well as to input from other disciplines that surely broaden our knowledge about radiation-induced local and systemic alterations.

Guest Editors

Prof. Dr. Udo S. Gaipl

Head of Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Germany

Dr. Lisa Deloch

Radiation Osteoimmunology, Translational Biology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany

Deadline for manuscript submissions

closed (31 December 2023)



an Open Access Journal by MDPI

Indexed in Scopus



mdpi.com/si/119641

Radiation Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 radiation@mdpi.com

mdpi.com/journal/radiation





an Open Access Journal by MDPI

Indexed in Scopus

mdpi.com/journal/

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Gabriele Multhoff

Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.5 days after submission; acceptance to publication is undertaken in 5.1 days (median values for papers published in this journal in the first half of 2025).

